Table 3.

Association of sotrovimab treatment with COVID-19 infection severity in matched treatment and control groups.

Study group	Severe/critical/fatalaCOVID-19	Mild/asymptomatic infection	Adjusted odds ratio (95% CI)
Main analysis
Controlsb	3	580	1.00
Sotrovimabb	4	341	2.67 (0.60-11.91)
Subgroup analysisc
Controlsd	8	525	1.00
Sotrovimabd	3	292	0.65 (0.17-2.48)
Restricting analyses to Omicron-dominated epidemic phase
Main analysis
Controlsb	0	431	1.00
Sotrovimabb	2	231	-e
Subgroup analysisc
Controlsd	4	387	1.00
Sotrovimabd	2	208	0.88 (0.16-4.89)

^aSeverity (2021), criticality (2021), and fatality (2021) were defined according to the World Health Organization guidelines.

^bCases and controls were exact-matched one-to-two by vaccination status, prior infection status, sex, age group, nationality group, comorbidity count, and epidemic phase. Matching factors are described in detail in Table 1.

^cSubgroup analysis was performed on a subsample that includes only immunocompromised individuals (solid organ or hematopoietic stem cell transplant recipients, patients receiving chemotherapy or immunosuppressive treatments, patients with severe immunodeficiency, and HIV patients), unvaccinated individuals, those ≥75 years of age, and pregnant women.

^dCases and controls were exact-matched 1:2 by vaccination status, prior infection status, sex, age group, nationality group, and epidemic phase. Matching factors are described in detail in Table 2.

^eCIs could not be estimated through conditional logistic regression because of zero events among controls.